We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc (TDOC) Outperforms Broader Market: What You Need to Know
Read MoreHide Full Article
The latest trading session saw Teladoc (TDOC - Free Report) ending at $7.40, denoting a +1.79% adjustment from its last day's close. The stock's change was more than the S&P 500's daily gain of 0.09%.
The telehealth services provider's stock has climbed by 2.25% in the past month, exceeding the Medical sector's gain of 2.17% and lagging the S&P 500's gain of 7.21%.
The upcoming earnings release of Teladoc will be of great interest to investors. The company is predicted to post an EPS of -$0.23, indicating a 17.86% growth compared to the equivalent quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $621.92 million, indicating a 3.19% decline compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates project earnings of -$1.17 per share and a revenue of $2.51 billion, demonstrating changes of +80.07% and -2.15%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Teladoc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an 8.56% increase. Currently, Teladoc is carrying a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 68, which puts it in the top 28% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teladoc (TDOC) Outperforms Broader Market: What You Need to Know
The latest trading session saw Teladoc (TDOC - Free Report) ending at $7.40, denoting a +1.79% adjustment from its last day's close. The stock's change was more than the S&P 500's daily gain of 0.09%.
The telehealth services provider's stock has climbed by 2.25% in the past month, exceeding the Medical sector's gain of 2.17% and lagging the S&P 500's gain of 7.21%.
The upcoming earnings release of Teladoc will be of great interest to investors. The company is predicted to post an EPS of -$0.23, indicating a 17.86% growth compared to the equivalent quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $621.92 million, indicating a 3.19% decline compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates project earnings of -$1.17 per share and a revenue of $2.51 billion, demonstrating changes of +80.07% and -2.15%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Teladoc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an 8.56% increase. Currently, Teladoc is carrying a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 68, which puts it in the top 28% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.